BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 20037302)

  • 21. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
    Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma.
    Hsu C; Huang CS; Chao TY; Lu YS; Bu CF; Chen MM; Chang KJ; Cheng AL
    Cancer; 2002 Nov; 95(10):2044-50. PubMed ID: 12412156
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Weekly paclitaxel with epirubicin as second-line therapy of metastatic breast cancer: results of a clinical phase II study.
    Köhler U; Olbricht SS; Fuechsel G; Kettner E; Richter B; Ridwelski K
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-40-S17-43. PubMed ID: 9374091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Weekly paclitaxel in women with heavily pretreated metastatic breast cancer: a retrospective analysis of cases treated at the Chang Gung Memorial Hospital.
    Lu CH; Lin YC; Chang HK
    Chang Gung Med J; 2007; 30(1):33-40. PubMed ID: 17477027
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Plasma concentrations of toremifene citrate and N-desmethyltoremifene in postmenopausal patients with breast cancer--comparison of 120 mg of toremifene citrate administered once a day and divided into 3 separate doses (t.i.d.)].
    Shiba E; Watanabe T; Taguchi T; Tsukamoto F; Noguchi S
    Gan To Kagaku Ryoho; 2000 Feb; 27(2):245-9. PubMed ID: 10700895
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I/II study with paclitaxel in combination with weekly high-dose 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer: an interim analysis.
    Klaassen U; Wilke H; Pari CP; Strumberg D; Harstrick A; Eberhardt W; Becher R; Diergarten K; Seeber S
    Semin Oncol; 1995 Dec; 22(6 Suppl 14):7-11. PubMed ID: 8553083
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I dose finding study evaluating the combination of bendamustine with weekly paclitaxel in patients with pre-treated metastatic breast cancer: RiTa trial.
    Loibl S; Murmann C; Schwedler K; Warm M; Müller L; Heinrich G; Nekljudova V; von Minckwitz G
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):953-8. PubMed ID: 18716777
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Weekly high-dose paclitaxel in metastatic and locally advanced breast cancer: a preliminary report.
    Akerley W; Sikov WM; Cummings F; Safran H; Strenger R; Marchant D
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-87-S17-90. PubMed ID: 9374102
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer.
    Dombernowsky P; Gehl J; Boesgaard M; Paaske T; Jensen BV
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):23-7. PubMed ID: 8893895
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience.
    Catimel G; Spielmann M; Dieras V; Tubiana-Hulin M; Bonneterre J; Pouillart P; Kayitalire L; Guastalla JP; Graffand N; Garet F; Dumortier A; Pellae-Cosset B
    Semin Oncol; 1997 Feb; 24(1 Suppl 3):S8-12. PubMed ID: 9071333
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Efficacy of high-dose toremifene as a second-line hormone therapy in patients with advanced or metastatic breast cancer resistant to aromatase inhibitor].
    Kubota O; Onuki Y; Uchiyama T; Oishi K; Takeda M
    Gan To Kagaku Ryoho; 2012 May; 39(5):753-7. PubMed ID: 22584326
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A study of the efficacy of high-dose toremifene in advanced and recurrent breast cancer].
    Tokura H; Fujisaki M; Takahashi T; Takigawa Y; Onouchi S; Matsuda K; Hirata A
    Gan To Kagaku Ryoho; 2012 Jul; 39(7):1071-3. PubMed ID: 22790041
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of high-dose toremifene therapy in postmenopausal patients with metastatic breast cancer resistant to aromatase inhibitors:a retrospective, single-institution study.
    Ishizuna K; Ninomiya J; Ogawa T; Tsuji E; Kojima M; Kawashima M; Nozaki M; Yamagishi H; Ueda Y; Oya M
    Gan To Kagaku Ryoho; 2014 Aug; 41(8):965-70. PubMed ID: 25132027
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A retrospective study of high-dose toremifene treatment for patients with aromatase inhibitor refractory advanced or metastatic hormone receptor-positive breast cancer].
    Koyama H; Iesato A; Fukushima Y; Okada T; Watanabe T; Harada M; Ito T; Maeno K; Mochizuki Y; Ito K; Amano J
    Gan To Kagaku Ryoho; 2011 Jul; 38(7):1123-6. PubMed ID: 21772095
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The clinical benefit of high-dose toremifene for metastatic breast cancer.
    Koike K; Edo M; Higaki M; Kitahara K; Satou S; Noshiro H
    Gan To Kagaku Ryoho; 2013 Jul; 40(7):877-80. PubMed ID: 23863727
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [A case of advanced breast cancer with multiple bone metastases responding to docetaxel and high-dose toremifene as fourth-line chemo-endocrine therapy].
    Minamoto K; Ikeda T
    Gan To Kagaku Ryoho; 2009 Dec; 36(13):2627-30. PubMed ID: 20009468
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II clinical trial of high-dose toremifene as primary hormone therapy in aromatase inhibitor-resistant breast cancer.
    Ogata H; Okamoto Y; Arima Y; Fukushima H; Takeyama H; Yamashita A; Kinoshita M; Suzuki N; Sawada T; Koshida Y; Matsui A; Tachibana A; Nakayama H; Oishi Y; Nogi H; Uchida K
    Gan To Kagaku Ryoho; 2013 Jun; 40(6):749-53. PubMed ID: 23863651
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Third- and Fourth-Line Chemotherapies including Paclitaxel and Bevacizumab for Metastatic Breast Cancer].
    Sakamoto M; Nio Y; Imai S; Uesugi K; Tamaoki M; Tamaoki M
    Gan To Kagaku Ryoho; 2017 Jul; 44(7):579-584. PubMed ID: 28790261
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Administration of low-dose albumin-bound paclitaxel for the treatment of advanced and recurrent breast cancer patients].
    Kawamura M; Nakano S; Kyoda S; Tabei I; Yoshida K; Takeyama H
    Gan To Kagaku Ryoho; 2013 Jul; 40(7):909-12. PubMed ID: 23863734
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and tolerability of weekly paclitaxel in combination with high-dose toremifene citrate in patients with metastatic breast cancer.
    Okita A; Saeki T; Aogi K; Osumi S; Takashima S; Okita R; Taira N; Kakishita T; Kurita A
    Acta Med Okayama; 2009 Aug; 63(4):187-94. PubMed ID: 19727203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.